Fidson, 10 others get licence to produce generic influenza drug
Nigerian pharmaceutical firm Fidson Healthcare is among 11 global manufacturers selected to produce generic versions of an influenza antiviral drug. The initiative, led by the Medicines Patent Pool and Roche, aims to improve pandemic preparedness.
Why it matters
Expanding generic manufacturing capacity in developing nations is essential for equitable access to life-saving medications during health crises.
Fidson Healthcare Plc , a Nigerian pharmaceutical manufacturing company, has been selected alongside 10 other manufacturers across nine countries to develop and manufacture generic versions of baloxavirmarboxil, an antiviral treatment for influenza, under a voluntary licensing agreement between the Medicines Patent Pool (MPP) and Roche.
The sublicence agreements are aimed at expanding manufacturing capacity, diversifying supply pathways for influenza treatment and strengthening preparedness for future outbreaks and pandemics, according to the MPP.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in